Neotherix was founded in September 2007 by Dr Mike Raxworthy and spun-out from Smith & Nephew (S&N) to develop and commercialise bioresorbable scaffolds for tissue regeneration and repair. Upon completion of the spin-out, Dr Peter Iddon joined Neotherix as Development Manager.

Neotherix' mission is to develop innovative products for soft tissue repair in acute (surgical and post-surgical) applications where there is a clear clinical need. Our technology is based on a considerable body of knowledge originally developed by project teams at the S&N Research Centre in York, UK, where Neotherix continues to be based. This technology, available to Neotherix for a wide range of non-chronic wound applications, is based around the polymer processing technique of electrospinning and will be exploited to produce bioresorbable tissue scaffolds tailored to the particular demands of target clinical indications.

Neotherix pursues a strategy of applying its platform technology to develop a pipeline of products for markets identified as appropriate and attractive on the basis of unmet clinical need. Our lead development is a tissue scaffold positioned for the repair of wounds resulting from the surgical excision of skin cancers. The American Academy of Dermatology has recognised this set of conditions to be at epidemic levels [1] and new treatment options need to be found to realise time and cost savings for health systems globally. Use of the Neotherix scaffold will provide the lead clinician with an effective and valuable additional resource. Beyond this initial focus, we expect our technology to be suitable for use in a number of other surgical procedures.

Dr Mike Raxworthy
Chief Executive Officer

Mike has extensive experience leading research and development projects in the medical device industry. Prior to founding Neotherix, he spent over eleven years with Smith & Nephew, his most recent position being Senior Support and Delivery Team Leader for the Wound Management business unit. He has also held positions with 3M Health Care and Pfizer and has over 20 years experience in wound healing research (gained through academic and industrial roles).

Mike gained a BSc in Applied Biology in 1978, a PhD in Biochemistry from the University of Leeds, UK in 1983 and an MBA from Warwick Business School, UK in 2001. He is a member of the European Tissue Repair Society, the British Society for Matrix Biology and the Tissue Engineering and Regenerative Medicine International Society. Mike is currently on the Steering Group of regeNer8 (the Centre for Translational Regenerative Medicine of the N8 group of research-intensive UK universities).

Dr Peter Iddon
Development Manager

Peter's expertise is in the area of polymer chemistry. Prior to joining Neotherix, Peter worked as a Biomaterials Scientist for the Wound Management business unit of Smith & Nephew. Peter has a degree in Chemistry from the University of York, UK and a PhD in Polymer Chemistry from the University of Sussex, UK. He is a member of the Royal Society of Chemistry.

1. American Academy of Dermatology 2007 (Dermatology World, May 2007 ) & 2010 (American Academy of Dermatology Testimony to FDA Hearing, March 2010 ).